|
|
Effect of Association of Temozolomide With Other
Chemotherapic Agents on Cell Growth Inhibition in Glioma Cell Lines
Marco Balzarotti, Emilio Ciusani, Chiara Calatozzolo, Danilo Croci,
Amerigo Boiardi, and Andrea Salmaggi
Laboratory of Clinical Investigation, Department of Neurology, National
Neurological Institute "C. Besta." Via Celoria 11, 20133 Milan, Italy
Address correspondence to Andrea Salmaggi, M.D., Department of Neurology,
National Neurological Institute "C. Besta," Via Celoria, 11, 20133
Milan, Italy. Tel: +39 02 2394247; Fax: +39 02 2394535; E-mail:
salmaggi@istituto-besta.it.
Despite progresses in surgery and treatments of malignant gliomas, prognosis
of these tumors remains poor, with a median life expectancy of 12 months in
glioblastomas.
Chemotherapy (mostly with nitrosoureas) has been demonstrated to
prolong overall survival, but the entity of this improvement is slight and
disease recurrence/progression is the rule, stressing the need for multimodality
treatment.
In this work we investigated the effect of association of
temozolomide (TMZ), an orally bioavailable alkylating agent, with three
chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP), and
topotecan (TP), on cell growth of A172, U373, U138, U87, and SW1783 (all human
glioma cell lines).
Results indicate a synergistic effect (CI < 1) of TMZ in
association with liposomal DOXO and CDDP on cell growth inhibition in most of
the studied cell lines (A172, U373, U138, U87).
Synergistic effect also has been
obtained after treatment of A172 and U373 with TMZ and TP in association.
In
conclusion, our results confirm the potential effect of association of
chemotherapic drugs with different mechanisms of action in the treatment of
gliomas.
Key words: Temozolomide; Doxorubicin; Cis-platinum; Topotecan; Glioma;
Locoregional
Copyright © 2004 Cognizant Comm. Corp.
Printed in the USA. All rights reserved.
Source: http://www.cognizantcommunication.com/filecabinet/Oncology/oradd14abs7.html#oradd14abs72
|
